Reimagining Health and Disease
More than 20,000 genes make us human. Genes control critical aspects of health and disease — but what controls our genes?
Foghorn Therapeutics is developing therapies based on a system that directs which genes our cells express, and when, where, and in what order.
By manipulating this system with our unique Gene Traffic ControlTM Product Platform, Foghorn will change how genes turn “on” and “off.” Unlike approaches that edit genes, this novel way of thinking will alter what our DNA has in store for us – and rewrite destiny for millions of people living with disease.
With the Gene Traffic ControlTM Product Platform, Foghorn® Therapeutics is discovering and developing an unprecedented class of medicines targeting diseases with genetically determined dependencies in the chromatin regulatory system. The company, currently pre-clinical stage, is rapidly advancing over 10 programs across a wide range of cancers and is beginning to explore other diseases.
Foghorn’s proprietary Gene Traffic ControlTM Product Platform is based on the company’s unique insights into the chromatin regulatory system and enables highly scalable drug discovery and development efforts.
a pioneering culture
Foghorn’s focus is on discovering, developing, and delivering revolutionary medicines to our fellow human beings.
We’re building a company that puts people first, never stops trying to battle disease, puts teamwork at the core of everything, and is driven by science to find new ways to think about solving disease.
Meet the minds behind Gene Traffic ControlTM Product Platform
Foghorn envisions a world where we will cure diseases from within. Learn more below about the people working to make this vision a reality.
A unique life science innovation enterprise, conceives, creates, resources and develops first-in-category life sciences companies. Since its launch in 2000, the firm has applied a proprietary, hypothesis-driven innovation process to originate and foster nearly 100 scientific ventures, resulting in over $20 billion in aggregate value, 500+ issued patents and more than 40 clinical trials for novel therapeutic agents.